SCHEMBL1003557

SCHEMBL1003557

Cc1cc(O)c2c(c1)Cc1cccc(O)c1C2=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.71
MAPT P10636 6/20 0.71
TDP1 Q9NUW8 5/20 0.71
ALOX15 P16050 5/20 0.71
TSHR P16473 4/20 0.71
MEN1 O00255 4/20 0.71
CYP3A4 P08684 4/20 0.71
KMT2A Q03164 4/20 0.71
HSD17B10 Q99714 4/20 0.71
USP2 O75604 2/20 0.71
THRB P10828 2/20 0.71
HPN P05981 1/20 0.71
ALOX5 P09917 1/20 0.71
PTGS1 P23219 1/20 0.71
PDE4A P27815 1/20 0.71
KDR P35968 1/20 0.71
SIRT5 Q9NXA8 1/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
HRH3 Q9Y5N1 1/20 0.71
MAPK1 P28482 4/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29929084 1.00 ALDH1A1 (0.71) ALDH1A1MAPTTDP1ALOX15TSHR
SCHEMBL31509436 1.00 ALDH1A1 (0.71) ALDH1A1MAPTTDP1ALOX15TSHR
Anthralin SCHEMBL29439039 0.84 MAPT (1.00) ALDH1A1MAPTTDP1ALOX15TSHR
Anthralin SCHEMBL3197 0.84 MAPT (1.00) ALDH1A1MAPTTDP1ALOX15TSHR
Anthralin SCHEMBL30013383 0.84 MAPT (1.00) ALDH1A1MAPTTDP1ALOX15TSHR
SCHEMBL14447684 0.83 MAOA (0.52) ALDH1A1MAPTTDP1ALOX15TSHR
Anthralin SCHEMBL7555831 0.82 MAPT (0.96) ALDH1A1MAPTTDP1ALOX15TSHR
Emodin Anthrone SCHEMBL6046328 0.81 ACLY (0.65) ALDH1A1MAPTTDP1ALOX15TSHR
Emodin Anthrone SCHEMBL31003276 0.81 ACLY (0.65) ALDH1A1MAPTTDP1ALOX15TSHR
Emodin Anthrone SCHEMBL29811113 0.81 ACLY (0.65) ALDH1A1MAPTTDP1ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 579 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025088629-A1 A NOVEL FEED-ADDITIVE COMPOSITION KYNTOX BIOTECH INDIA PRIVATE LIMITED (IN) 2025-05-01 WO claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
CN-107745559-B Thermal indicator, container and application 深圳九星印刷包装集团有限公司 2020-04-28 CN claimed
CN-108967788-A A kind of apple ferment drink rich in fruit anthocyanidin and preparation method thereof and device 谭建新 2018-12-11 CN claimed
CN-104147017-B Medicinal composition for treating liver cirrhosis and application thereof 新乡医学院第附属医院 2017-02-08 CN claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-1244435-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES Proteotech Inc. (US) 2002-10-02 EP claimed
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases PROTAMED, INC. 2001-11-29 US claimed
WO-2001049281-A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES PROTEOTECH, INC. (US) 2001-07-12 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-4885244-A CONTACTING MICROORGANISM WITH SACCHARIDE IN POLYHYDRIC AROMATIC COMPOUND CONTAINING MEDIUM; HIGH MOLECULAR WEIGHT MITSUBISHI RAYON CO., LTD. (JP) 1989-12-05 US claimed
US-4788061-A Extended occlusive treatment of skin disorders SHORE RONALD N (US) 1988-11-29 US claimed
US-4699929-A CARRIER OF LIQUID PARAFFIN, SOLID PARAFFIN AND MICROCRYSTALLINE WAX MAKES DRUG OXIDATION RESITS ORION-YHTYMA OY (FI) 1987-10-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB ALDH1A1 2722/4885MAPT 3926/4885TDP1 3469/4885
US-20010047032-A1 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases SNCA, PARK7, HTT ALDH1A1 1370/4885MAPT 4/4885TDP1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.